Holen Sie sich die Stockscreener-App
215.31
3.06%
-6.79
Handel nachbörslich:
215.31
Schlusskurs vom Vortag:
$222.10
Offen:
$218.19
24-Stunden-Volumen:
848.90K
Relative Volume:
0.60
Marktkapitalisierung:
$30.84B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-131.19
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
-3.61%
1M Leistung:
+4.13%
6M Leistung:
-11.96%
1J Leistung:
+30.09%
1-Tages-Spanne:
$214.82
$222.13
1-Wochen-Bereich:
$204.16
$227.90
52-Wochen-Spanne:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
215.31 | 31.81B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera CEO Steven Chapman sells $9.09 million in company stock By Investing.com - Investing.com India
Natera (NTRA) CEO Chapman sells 41,124 shares under 10b5-1 plan - stocktitan.net
Natera CEO Steven Chapman sells $9.09 million in company stock - Investing.com
(NTRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
[144] Natera, Inc. SEC Filing - stocktitan.net
Natera (NTRA) appoints independent director Thomas Lynch and expands board - stocktitan.net
Natera executive chairman sells $1.64m in shares - Investing.com
NTRA Initiates Coverage On Goldman Sachs -- Rating Set to Neutra - GuruFocus
Natera, Inc. Earnings and Revenue – XETR:45E - TradingView
Natera to launch enhanced Panorama NIPT for low fetal fractions - MSN
Goldman Sachs initiates Natera stock with Neutral rating, $245 target - Investing.com UK
Goldman Sachs initiates Natera stock with Neutral rating, $245 target By Investing.com - Investing.com India
Natera CytoDyn Signatera Pact Highlights Data Assets And Rich Valuation - simplywall.st
Natera partners with CytoDyn on cancer treatment research By Investing.com - Investing.com South Africa
Steven L. Chapman reports common‑share sales (NASDAQ: NTRA) - stocktitan.net
CytoDyn (CYDY) Teams Up with Natera for Cancer Research Collaboration - GuruFocus
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer - CytoDyn Inc.
Natera Inc stock (US6323071042): insider sales and new oncology board appointments in focus - AD HOC NEWS
Natera expands Austin operations with new sequencing facility - MSN
Natera, CytoDyn Partner in Colorectal Cancer Study - Contract Pharma
Natera partners with CytoDyn on cancer treatment research - Investing.com
DNA blood test to track tumors in new colon cancer drug trial - Stock Titan
Natera adds two oncology experts to board of directors - Investing.com UK
NTRA & Diakonos partner to use Signatera in refractory melanoma trial - MSN
Insider Sell Alert: Solomon Moshkevich Sells 3,000 Shares of Nat - GuruFocus
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors - BioSpace
Natera president sells $655,294 of common stock - Investing.com
Natera (NTRA) clinical diagnostics president sells 3,000 shares under 10b5-1 plan - stocktitan.net
Natera president sells $655,294 of common stock By Investing.com - Investing.com Canada
Natera(NTRA.US) Director Sells US$17.18 Million in Common Stock - Moomoo
Director Roelof Botha-linked vehicles sell 78K Natera (NTRA) shares - stocktitan.net
Natera Adds Oncology Veterans Thomas Lynch and Eric Rubin to Board - citybiz
IVF Patients Say Natera Profited Off Ineffective Embryo Tests - Law360
Natera adds two oncology experts to board of directors By Investing.com - Investing.com Australia
Did Supreme Court’s Refusal to Hear Natera Appeal Just Shift CareDx’s (CDNA) Investment Narrative? - simplywall.st
NTRA Assumed by Wolfe Research -- Rating Upgraded to Outperform - GuruFocus
Wolfe Research initiates Natera stock coverage with outperform rating - Investing.com UK
Natera Inc stock (US6323071042): Wolfe Research initiation and recent price action in focus - AD HOC NEWS
Wolfe Research initiates Natera stock coverage with outperform rating By Investing.com - Investing.com South Africa
NTRA (NASDAQ: NTRA) insider sells multiple lots, files to resell 3,000 shares - stocktitan.net
U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute - Reuters
U.S. Supreme Court rejects Natera, CareDx false-advertising dispute - TradingView
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial - Yahoo Finance
Natera And 2 Other Companies That May Be Trading Below Their Estimated Value - Yahoo Finance
Natera, Inc. (NTRA) Stock Analysis: Impressive Revenue Growth Amidst a Challenging Valuation Landscape - DirectorsTalk Interviews
Is Natera (NTRA) Quietly Redefining Its Moat With MRD Trials And Sequencing Scale-Up? - Yahoo Finance
Natera’s Solomon Moshkevich on how MRD testing pinpoints cancer recurrence - MedTech Dive
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):